CandlesenseCandlesense
News/Companies/CDXS

CDXS News

Codexis Announces Signing of Lease for GMP Manufacturing Facility

CDXS

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California.

November 10, 2025
Read more →

Codexis to Participate in Cantor Global Healthcare Conference

CDXS

REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York.

August 28, 2025Conference
Read more →

Codexis Reports Second Quarter 2025 Financial Results

CDXS

Announces revenue of $15.3M vs $14.1M analyst consensus estimate

August 13, 2025Earnings
Read more →

Codexis Presents Data At TIDES USA Showcasing Proprietary ECO Synthesis Platform's Ability To Support siRNA Manufacturing By Reducing Purification Costs, Improving Process Performance, And Demonstrating Potential To Control Stereochemistry

CDXS

May 22, 2025
Read more →

Codexis Affirms FY2025 Sales Guidance of $64.00M-$68.00M vs $65.67M Est

CDXS

May 14, 2025
Read more →

Codexis Q1 EPS $(0.25) Misses $(0.23) Estimate, Sales $7.54M Miss $9.66M Estimate

CDXS

May 14, 2025
Read more →

Codexis Secures First Revenue Deal For ECO Synthesis, Marks Milestone In Enzymatic siRNA Manufacturing

CDXS

March 24, 2025
Read more →

Codexis Sees FY2025 Sales $64.000M-$68.000M vs $66.61M Est

CDXS

February 27, 2025
Read more →

Codexis Q4 EPS $(0.13) Misses $(0.04) Estimate, Sales $21.46M Miss $27.41M Estimate

CDXS

February 27, 2025
Read more →

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

CDXS

November 15, 2024
Read more →

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

CDXS

November 14, 2024
Read more →

Codexis Affirms FY2024 Product revenues $38M-$42M, R&D revenues $18M-$22M.

CDXS

October 31, 2024
Read more →

Codexis Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $12.833M Beat $11.482M Estimate

CDXS

October 31, 2024
Read more →